Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression.

De Berardis D, Fornaro M, Serroni N, Campanella D, Rapini G, Olivieri L, Srinivasan V, Iasevoli F, Tomasetti C, De Bartolomeis A, Valchera A, Perna G, Mazza M, Di Nicola M, Martinotti G, Di Giannantonio M.

Int J Mol Sci. 2015 Jan 5;16(1):1111-30. doi: 10.3390/ijms16011111. Review.

2.

Role of the Toll Like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway.

Lucas K, Maes M.

Mol Neurobiol. 2013 Aug;48(1):190-204. doi: 10.1007/s12035-013-8425-7. Epub 2013 Feb 26. Review.

PMID:
23436141
3.

Agomelatine for Depression in Schizophrenia: A Case-Series.

Mutschler J, Rüsch N, Schönfelder H, Herwig U, Brühl AB, Grosshans M, Rössler W, Russmann H.

Psychopharmacol Bull. 2012 Feb 15;45(1):35-43.

4.

Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients.

Park HJ, Park JK, Kim SK, Cho AR, Kim JW, Yim SV, Chung JH.

J Mol Neurosci. 2011 Oct;45(2):304-8. doi: 10.1007/s12031-011-9522-6. Epub 2011 Apr 28.

PMID:
21526376
5.

[Novel insomnia drugs, including drugs currently under development].

Inada K.

Nihon Rinsho. 2009 Aug;67(8):1590-4. Review. Japanese.

PMID:
19768946
6.

Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study.

Shamir E, Barak Y, Shalman I, Laudon M, Zisapel N, Tarrasch R, Elizur A, Weizman R.

Arch Gen Psychiatry. 2001 Nov;58(11):1049-52.

PMID:
11695951

Supplemental Content

Loading ...
Support Center